Related Experiment Video

Updated: Jul 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

[Chronic hepatitis C. Epidemiology and therapeutic results in 255 cases]

A Pérez Mota1, M A Blanco Coronado, J Graus Morales

  • 1Servicio de Aparato Digestivo, Hospital Virgen de la Torre y Area Sanitaria 1, Madrid. arturopm@teleline.es

Anales De Medicina Interna (Madrid, Spain : 1984)
|October 28, 2006
PubMed

Insights

This study on chronic hepatitis C treatment found higher sustained viral response (SVR) rates with specific antiviral regimens. Adjusting treatment to body mass also yielded significant economic savings.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Chronic hepatitis C (HCV) affects a significant patient population.
  • Understanding epidemiological factors and treatment outcomes is crucial for effective management.
  • Genotype distribution influences treatment selection and efficacy.

Purpose of the Study:

  • To analyze epidemiological data of chronic hepatitis C patients.
  • To evaluate the efficacy of different antiviral treatment regimens based on HCV genotype.
  • To assess the economic impact of treatment adjustments.

Main Methods:

  • Retrospective review of 255 chronic hepatitis C patients diagnosed between 2003 and August 2005.
  • Categorization of patients by HCV genotype (1, 2, 3, and 4).
  • Comparison of treatment outcomes using PEG-Interferon alpha-2b + Ribavirin versus Interferon alpha 2b + Ribavirin, with body mass-adjusted dosing.

Main Results:

  • Genotype 1 (79.05%) was the most prevalent, followed by genotype 3 (14.22%).
  • Sustained viral response (SVR) rates were 61.95% for genotypes 1 and 4, and 85% for genotypes 3 and 2.
  • Body mass-adjusted treatment led to an average saving of 868.94 Euro per case.
  • Previous monotherapy with Interferon showed a significantly lower SVR (31.25%) compared to combination therapy.

Conclusions:

  • Combination antiviral therapy, tailored to HCV genotype, achieves high SVR rates.
  • Body mass-adjusted dosing is effective and economically beneficial.
  • Combined therapy offers superior outcomes compared to Interferon monotherapy for chronic hepatitis C.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: